Kodiak Sciences Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Kodiak Sciences Inc Unternehmen

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Kodiak Sciences Inc Informationen



BörsenkürzelKOD

Name des UnternehmensKodiak Sciences Inc

IPO-datumOct 04, 2018

CEOPerlroth (Victor)

Anzahl der mitarbeiter109

WertpapierartOrdinary Share

GeschäftsjahresendeOct 04

Addresse1250 Page Mill Rd

StadtPALO ALTO

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl94304

Telefon16502810850

Websitehttps://kodiak.com/

BörsenkürzelKOD

IPO-datumOct 04, 2018

CEOPerlroth (Victor)

Führungskräfte von Kodiak Sciences Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

183.32K

+1152.00%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

--

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

--

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

--

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Felix J. Baker, Ph.D.

Independent Director

--

Dr. Bassil I. Dahiyat, Ph.D.

Independent Director

--

Dr. Taiyin Yang, Ph.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

183.32K

+1152.00%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

--

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

--

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

--

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Felix J. Baker, Ph.D.

Independent Director

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, Feb 8

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Baker Bros. Advisors LP

32.66%

Point72 Asset Management, L.P.

4.65%

Perlroth (Victor D)

4.42%

BlackRock Institutional Trust Company, N.A.

3.93%

The Vanguard Group, Inc.

3.79%

Andere

50.55%

Aktionäre

Anteil

Baker Bros. Advisors LP

32.66%

Point72 Asset Management, L.P.

4.65%

Perlroth (Victor D)

4.42%

BlackRock Institutional Trust Company, N.A.

3.93%

The Vanguard Group, Inc.

3.79%

Andere

50.55%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

46.25%

Investment Advisor

19.99%

Investment Advisor/Hedge Fund

9.35%

Individual Investor

4.78%

Research Firm

1.78%

Endowment Fund

1.13%

Private Equity

1.04%

Pension Fund

0.17%

Sovereign Wealth Fund

0.08%

Andere

15.43%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

262

48.78M

79.97%

+1.55M

2025Q3

248

41.93M

79.39%

-9.11M

2025Q2

273

46.04M

87.25%

-8.67M

2025Q1

302

46.32M

87.78%

-8.84M

2024Q4

308

44.88M

85.29%

-7.98M

2024Q3

318

42.74M

81.24%

-12.36M

2024Q2

326

43.49M

82.78%

-12.58M

2024Q1

345

46.64M

88.83%

-7.18M

2023Q4

377

44.39M

84.60%

-13.12M

2023Q3

391

45.97M

87.64%

-8.18M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Baker Bros. Advisors LP

19.92M

32.66%

+2.61M

+15.07%

Dec 18, 2025

Point72 Asset Management, L.P.

2.84M

4.65%

+2.38M

+526.72%

Sep 30, 2025

Perlroth (Victor D)

2.70M

4.42%

+527.00K

+24.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

2.40M

3.93%

-286.86K

-10.68%

Sep 30, 2025

The Vanguard Group, Inc.

1.95M

3.2%

+127.99K

+7.02%

Sep 30, 2025

Adage Capital Management, L.P.

1.33M

2.19%

-720.71K

-35.06%

Sep 30, 2025

ICONIQ Capital, LLC

1.27M

2.08%

--

Sep 30, 2025

TCG Crossover Management, LLC

1.15M

1.88%

--

Sep 30, 2025

SilverArc Capital Management, LLC

1.00M

1.64%

+598.46K

+149.04%

Sep 30, 2025

Acadian Asset Management LLC

969.91K

1.59%

-999.97K

-50.76%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

Fidelity Enhanced Small Cap ETF

0.18%

iShares Micro-Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.11%

Invesco RAFI US 1500 Small-Mid ETF

0.06%

iShares Health Innovation Active ETF

0.06%

iShares Russell 2000 Value ETF

0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

0.05%

ProShares Hedge Replication ETF

0.03%

ProShares UltraPro Russell2000

0.03%

Proshares Ultra Russell 2000

0.02%

Fidelity Enhanced Small Cap ETF

Anteil0.18%

iShares Micro-Cap ETF

Anteil0.11%

Vanguard US Momentum Factor ETF

Anteil0.11%

Invesco RAFI US 1500 Small-Mid ETF

Anteil0.06%

iShares Health Innovation Active ETF

Anteil0.06%

iShares Russell 2000 Value ETF

Anteil0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

Anteil0.05%

ProShares Hedge Replication ETF

Anteil0.03%

ProShares UltraPro Russell2000

Anteil0.03%

Proshares Ultra Russell 2000

Anteil0.02%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten